07.08.2020 • NewsAstraZenecaDede Willams

AstraZeneca Licenses Covid Candidate to China

In a much heeded licensing deal, AstraZeneca (AZ) has awarded Chinese pharma BioKangta sole commercial rights to its AZD1222 Covid-19 vaccine candidate in the People’s Republic. The UK drugmaker is developing the adenovirus vector-based vaccine on behalf of Oxford University, which created it.

Financial terms of the arrangement were not disclosed. AstraZeneca said the two companies additionally will explore the possibility of jointly producing the vaccine in China for other markets.

Along with commercialization rights, BioKangta will also have the right to exclusive clinical development and production in its home market. In exchange, the Chinese company will reserve enough capacity to make at least 100 million doses by the end of 2020 and expand this to 200 million doses per year by the end of 2021.

Altogether, AZ hopes to produce 2 billion doses of the vaccine worldwide by the end of 2021. It has already pledged to supply 300 million doses to each to the US and the EU, as well as 100 million doses to the UK and up to 100 million doses to Brazil. 

The drugmaker also has signed a manufacturing and distribution agreement with R-Pharm in Russia and with the Serum Institute of India to provide an unspecified number of doses for for low-income countries.

SK Bioscience, part of the Korean SK conglomerate, recently signed up to produce the AZ Covid candidate in its home market, and Daiichi Sankyo has confirmed it is in discussions to supply the vaccine in Japan.

The candidate, which entered phase 2/3 clinical trials in May, has been shown to trigger both antibody and T-cell immune responses and has received praise from US infectious disease expert Anthony Fauci.

The British pharma is seen as one of the leading Western players on the Chinese drugs market, the company’s second largest behind the US, accounting for about 20% of its business.

The AZ/Oxford Covid vaccine is only the third foreign candidate in which China has shown an interest, trade journal Fierce Pharma said. Fosun Pharma holds Chinese rights to BioNTech’s mRNA program through a $135 million agreement, while Inovio has partnered with Beijing Advaccine Biotechnology on a DNA vaccine candidate with the working title of INO-4800. China is also developing its own vaccines.

Australia has sealed a deal with AstraZeneca to supply enough doses of its...
Australia has sealed a deal with AstraZeneca to supply enough doses of its Covid-19 vaccine being developed on behalf of Oxford University to inoculate 95% of the country’s 25 million people. Plans call for local manufacture. Financial details are still to be worked out. (c) AstraZeneca

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.